

# Arkansas Blue Cross and Blue Shield FEP Drug List

The purpose of this document is to provide the location of the medical necessity criteria that Prime Therapeutics Management will require to render clinical determinations for the Medical Pharmacy Prior Approval program. Additional information can be obtained by visiting the FEP website. **Please note that both websites also contain links to policies that are not managed in the prior approval program administered by Prime Therapeutics Rx Management on behalf of Arkansas Blue Cross and Blue Shield FEP.**

HCPDS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J3262	Actemra IV	tocilizumab	BDAID: Rheumatoid Arthritis	3/1/2022	5.70.12	<a href="#">CVS</a>
J0800	Acthar HP	corticotropin	Corticotropin, Acth	3/1/2022	40328	<a href="#">CVS</a>
J0791	Adakveo	crizanlizumab-tmca	Rare Disease	3/1/2022	5.85.36	<a href="#">CVS</a>
J9042	Adcetris	brentuximab vedotin	Oncology	3/1/2022	43606	<a href="#">CVS</a>
J1454	Akynzeo IV	fosnetupitant/palonosetron	Antiemetics	3/1/2022	5.50.05	<a href="#">CVS</a>
J2469	Aloxi	palonosetron	Antiemetics	3/1/2022	5.50.15	<a href="#">CVS</a>
Q5126	Alymsys	bevacizumab-maly	Oncology	1/1/2024	5.21.004	<a href="#">CVS</a>
J0225	Amvuttra	vutrisiran		1/1/2024	5.75.037	<a href="#">CVS</a>
J0256	Aralast NP	alpha 1-proteinase inhibitor	Alpha-1 Proteinase Inhibitor (For Emphysema)	3/1/2022	5.45.09	<a href="#">CVS</a>
J0881	Aranesp (non-ESRD)	darbepoetin	Erythropoiesis-Stimulating Agents	3/1/2022	5.85.01	<a href="#">CVS</a>
J9302	Arzerra	ofatumumab	Oncology	3/1/2022	37762	<a href="#">CVS</a>
J1554	Asceniv	immune globulin intravenous, human – slra	Immune Globulin	3/1/2022	37761	<a href="#">CVS</a>
J9035	Avastin (oncology only)	bevacizumab	Oncology	3/1/2022	5.21.004	<a href="#">CVS</a>
Q5121	Avsola	infliximab-axxq	BDAID	3/1/2022	5.50.002	<a href="#">CVS</a>
J9023	Bavencio	avelumab	Oncology	3/1/2022	32649	<a href="#">CVS</a>
J9032	Beleodaq	belinostat	Oncology	3/1/2022	54199	<a href="#">CVS</a>
J9036	Belrapzo	bendamustine	Oncology	3/1/2022	52372	<a href="#">CVS</a>
J9058	Bendamustine - Apotex	bendamustine (Apotex)	Oncology	7/1/2023	5.21.043	<a href="#">CVS</a>
J9059	Bendamustine - Baxter	bendamustine (Baxter)	Oncology	7/1/2023	5.21.043	<a href="#">CVS</a>
J9034	Bendeka	bendamustine	Oncology	3/1/2022	5.21.043	<a href="#">CVS</a>
J0490	Benlysta IV	belimumab	BDAID: Systemic Lupus Erythematosus	3/1/2022	5.99.01	<a href="#">CVS</a>
J0179	Beovu	brolicizumab-dbll	Ophthalmic Injections	3/1/2022	5.90.026	<a href="#">CVS</a>
J0597	Berinerit	c1 esterase inhibitor (human)	Hereditary Angioedema	3/1/2022	5.85.02	<a href="#">CVS</a>
J9229	Besponsa	inotuzumab ozogamicin	Oncology	3/1/2022	5.21.100	<a href="#">CVS</a>
J1556	Bivigam	intravenous immune globulin	Immune Globulin	3/1/2022	37761	<a href="#">CVS</a>
J9039	Blinicyto	blinatumomab	Oncology	3/1/2022	18769	<a href="#">CVS</a>
J9046	Bortezomib	bortezomib	Oncology	3/1/2022	5.21.045	<a href="#">CVS</a>

HCPCS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J9048	Bortezomib	bortezomib	Oncology	3/1/2022	5.21.045	<a href="#">CVS</a>
J9049	Bortezomib	bortezomib	Oncology	3/1/2022	5.21.045	<a href="#">CVS</a>
J9051	Bortezomib	bortezomib (Maia)	Oncology	10/1/2023	5.21.045	<a href="#">CVS</a>
J0585	Botox	onabotulinumtoxina	Botulinum Toxins	3/1/2022	5.75.01	<a href="#">CVS</a>
Q5124	Byooviz	ranibizumab-nuna	Ophthalmic Injections	1/1/2024	5.90.029	<a href="#">CVS</a>
J1786	Cerezyme	imiglucerase	Enzyme Replacement Therapy	3/1/2022	5.85.04	<a href="#">CVS</a>
Q5128	Cimerli	ranibizumab-eqrn	Ophthalmic Injections	1/1/2024	5.90.029	<a href="#">CVS</a>
J0717	Cimzia	certolizumab pegol	BDAID	3/1/2022	5.50.11	<a href="#">CVS</a>
J2786	Cinqair	reslizumab	Asthma/COPD	3/1/2022	5.45.08	<a href="#">CVS</a>
J0598	Cinryze	c-1 esterase inhibitor human	Hereditary Angioedema	3/1/2022	5.85.05	<a href="#">CVS</a>
J0584	Crysvita	burosumab-twza	Enzyme Replacement Therapy	3/1/2022	19144	<a href="#">CVS</a>
90284/ J3590	Cutaquig	immune globulin subcutaneous (human) - hipp	Immune Globulin	3/1/2022	39588	<a href="#">CVS</a>
J1555	Cuvitru	subcutaneous immune globulin	Immune Globulin	3/1/2022	39588	<a href="#">CVS</a>
J9308	Cyramza	ramucirumab	Oncology	3/1/2022	52738	<a href="#">CVS</a>
J9145	Darzalex	daratumumab	Oncology	3/1/2022	25709	<a href="#">CVS</a>
J9144	Darzalex Faspro	daratumumab; hyaluronidase-fihj	Oncology	3/1/2022	5.21.147	<a href="#">CVS</a>
J7318	Durolane	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
J0586	Dysport	abobotulinumtoxina	Botulinum Toxins	3/1/2022	5.75.02	<a href="#">CVS</a>
J3060	Elleyso	taliglucerase alfa	Enzyme Replacement Therapy	3/1/2022	5.85.14	<a href="#">CVS</a>
J9176	Empliciti	elotuzumab	Oncology	3/1/2022	26805	<a href="#">CVS</a>
J9358	Enhertu	fam-trastuzumab deruxtecan-nxki	Oncology	3/1/2022	5.21.138	<a href="#">CVS</a>
J3380	Entyvio	vedolizumab	BDAID: Crohns Disease/Ulcerative Colitis	3/1/2022	5.50.12	<a href="#">CVS</a>
J1325	Epoprostenol	epoprostenol	Pulmonary Arterial Hypertension	3/1/2022	5.40.15	<a href="#">CVS</a>
J9055	Erbitux	cetuximab	Oncology	3/1/2022	30823	<a href="#">CVS</a>
J7323	Euflexxa	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09	<a href="#">CVS</a>
J3111	Evenity	romosozumab-aqqg	Osteoporosis	3/1/2022	23161	<a href="#">CVS</a>
J1428	Exondys 51	eteplirsen	CNS Agents: Rare Diseases	3/1/2022	5.75.14	<a href="#">CVS</a>
J0178	Eylea	aflibercept	Ophthalmic Injections	3/1/2022	5.90.026	<a href="#">CVS</a>
J0517	Fasenra	benralizumab	Asthma/COPD	3/1/2022	5.45.07	<a href="#">CVS</a>
J9155	Firmagon	degarelix	Oncology	3/1/2022	50920	<a href="#">CVS</a>
J1572	Flebogamma	intravenous immune globulin	Immune Globulin	3/1/2022	37761	<a href="#">CVS</a>
J1325	Flolan	"epoprostenol (flolan/veltri)"	Pulmonary Arterial Hypertension	3/1/2022	5.40.15	<a href="#">CVS</a>
Q5108	Fulphila	pegfilgrastim-jmdb	Colony-Stimulating Factors	3/1/2022	5.85.009	<a href="#">CVS</a>
Q5130	Fylnetra	pegfilgrastim-pbbk	Colony-Stimulating Factors	1/1/2024	5.85.009	<a href="#">CVS</a>
J1569	Gammagard Liquid	intravenous immune globulin	Immune Globulin	3/1/2022	37761	<a href="#">CVS</a>

HCPCS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J1566	Gammagard S/D (powder)	immune globulin	Immune Globulin	3/1/2022	37761	<a href="#">CVS</a>
J1561	Gammaked	intravenous immune globulin	Immune Globulin	3/1/2022	37761	<a href="#">CVS</a>
J1557	Gammaplex	intravenous immune globulin	Immune Globulin	3/1/2022	37761	<a href="#">CVS</a>
J1561	Gamunex-C	intravenous immune globulin	Immune Globulin	3/1/2022	37761	<a href="#">CVS</a>
J9301	Gazyva	obinutuzumab	Oncology	3/1/2022	47259	<a href="#">CVS</a>
J7326	Gel-One	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
J7328	Gel-Syn	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
J7320	GenVisc 850	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
J0223	Givlaari	givosiran	Rare Disease	1/1/2023	5.85.037	<a href="#">CVS</a>
J0257	Glassia	alpha 1-proteinase inhibitor	Alpha-1 Proteinase Inhibitor (For Emphysema)	3/1/2022	5.45.09	<a href="#">CVS</a>
J1447	Granix	tbo-filgrastim	Colony-Stimulating Factors	3/1/2022	5.85.010	<a href="#">CVS</a>
J0599	Haegarda	c1-esterase inhibitor	Hereditary Angioedema	3/1/2022	5.85.26	<a href="#">CVS</a>
J9179	Halaven	eribulin	Oncology	3/1/2022	27901	<a href="#">CVS</a>
J9355	Herceptin	trastuzumab	Oncology	3/1/2022	5.21.2006	<a href="#">CVS</a>
J9356	Herceptin Hylecta	hyaluronidase-oysk/trastuzumab	Oncology	3/1/2022	5.21.126	<a href="#">CVS</a>
Q5113	Herzuma	trastuzumab-pkrb	Oncology	3/1/2022	5.21.2006	<a href="#">CVS</a>
J1559	Hizentra	injection, immune globulin	Immune Globulin	3/1/2022	39588	<a href="#">CVS</a>
J7321	Hyalgan	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
J7322	Hymovis	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
J1575	HyQvia	injection, immune globulin/ hyaluronidase	Immune Globulin	3/1/2022	39588	<a href="#">CVS</a>
J3245	Ilumya	tildrakizumab	BDAID: Psoriasis/Psoriatic Arthritis	3/1/2022	5.90.35	<a href="#">CVS</a>
J9173	Imfinzi	durvalumab	Oncology	3/1/2022	34475	<a href="#">CVS</a>
Q5103	Inflectra	infliximab-dyyb	Autoimmune	3/1/2022	5.50.002	<a href="#">CVS</a>
J9043	Jevtana	cabazitaxel	Oncology	3/1/2022	46528	<a href="#">CVS</a>
J9064	Jevtana	Cabazitaxel (sandoz)	Oncology	10/1/2023	5.21.027	<a href="#">CVS</a>
J9354	Kadcyla	ado-trastuzumab emtansine	Oncology	3/1/2022	48355	<a href="#">CVS</a>
J1290	Kalbitor	ecallantide	Hereditary Angioedema	3/1/2022	5.85.07	<a href="#">CVS</a>
Q5117	Kanjinti	trastuzumab-anns	Oncology	3/1/2022	5.21.2006	<a href="#">CVS</a>
J9271	Keytruda	pembrolizumab	Oncology	3/1/2022	18404	<a href="#">CVS</a>
J2507	Krystexxa	pegloticase	Gout	3/1/2022	5.70.14	<a href="#">CVS</a>
J9047	Kyprolis	carfilzomib	Oncology	3/1/2022	45433	<a href="#">CVS</a>
J0202	Lemtrada	alemtuzumab	Multiple Sclerosis	3/1/2022	5.60.23	<a href="#">CVS</a>
J2820	Leukine	sargramostim	Colony-Stimulating Factors	3/1/2022	5.85.08	<a href="#">CVS</a>
J9119	Libtayo	cemiplimab-rwlc	Oncology	3/1/2022	5.21.118	<a href="#">FEP</a>
J2778	Lucentis	ranizumab	Ophthalmic Injections	3/1/2022	5.90.029	<a href="#">CVS</a>

HCPDS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J3398	Luxturna	voretigene	Ophthalmic Injections	3/1/2022	5.90.33	<a href="#">FEP</a>
J0888	Mircera (non ESRD)	epoetin beta	Erythropoiesis-Stimulating Agents	3/1/2022	5.85.21	<a href="#">CVS</a>
J7327	Monovisc	hyaluronic acid	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
Q5107	Mvasi	bevacizumab-awwb	Oncology	3/1/2022	38128	<a href="#">CVS</a>
J0587	Myobloc	rimabotulinumtoxinb	Botulinum Toxins	3/1/2022	5.75.03	<a href="#">CVS</a>
J2506	Neulasta	pegfilgrastim	Colony-Stimulating Factors	3/1/2022	5.85.009	<a href="#">CVS</a>
J1442	Neupogen	filgrastim	Colony-Stimulating Factors	3/1/2022	5.85.010	<a href="#">CVS</a>
Q5110	Nivestym	filgrastim-aafi	Colony-Stimulating Factors	3/1/2022	5.85.010	<a href="#">CVS</a>
J2796	Nplate	romiplostim	Hematology	3/1/2022	5.85.20	<a href="#">CVS</a>
J2182	Nucala	meprolizumab	Asthma/COPD	3/1/2022	5.45.07	<a href="#">CVS</a>
Q5122	Nyvepria	pegfilgrastim-apgf	Colony-Stimulating Factors	3/1/2022	5.85.009	<a href="#">CVS</a>
J2350	Ocrevus	ocrelizumab	Multiple Sclerosis	3/1/2022	5.60.28	<a href="#">CVS</a>
J1568	Octagam	intravenous immune globulin	Immune Globulin	3/1/2022	37761	<a href="#">CVS</a>
Q5114	Ogivri	trastuzumab-dkst	Oncology	3/1/2022	5.21.2006	<a href="#">CVS</a>
J9205	Onivyde	irinotecan liposome	Oncology	3/1/2022	24613	<a href="#">CVS</a>
J0222	Onpattro	patisiran	Rare Disease	3/1/2022	5.75.23	<a href="#">FEP</a>
Q5112	Ontruzant	trastuzumab-dttb	Oncology	3/1/2022	5.21.2006	<a href="#">CVS</a>
J9299	Opdivo	nivolumab	Oncology	3/1/2022	19500	<a href="#">CVS</a>
J0129	Orencia IV	abatacept	BDAID: Rheumatoid Arthritis	3/1/2022	5.70.18	<a href="#">CVS</a>
J7324	Orthovisc	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
J0224	Oxlumo	lumasiran	Rare Disease	1/1/2023	5.55.002	<a href="#">CVS</a>
J9177	Padcev	enfortumab vedotin-ejfv	Oncology	3/1/2022	5.21.137	<a href="#">CVS</a>
J1599	Panzyga	intravenous immune globulin	Immune Globulin	3/1/2022	37761	<a href="#">CVS</a>
J9306	Perjeta	pertuzumab	Oncology	3/1/2022	43972	<a href="#">CVS</a>
J9309	Polivy	polatuzumab vedotin-piiq	Oncology	3/1/2022	5.21.129	<a href="#">CVS</a>
J9295	Portrazza	necitumumab	Oncology	3/1/2022	26440	<a href="#">CVS</a>
J9204	Poteligeo	mogamulizumab-kpkc	Oncology	3/1/2022	5.21.114	<a href="#">CVS</a>
J1459	Privigen	intravenous immune globulin	Immune Globulin	3/1/2022	37761	<a href="#">CVS</a>
J0885	Procrit/Epogen (non ESRD)	epoetin alfa	Erythropoiesis-Stimulating Agents	3/1/2022	5.85.06	<a href="#">CVS</a>
J0256	Prolastin-C	alpha 1-proteinase inhibitor	Alpha-1 Proteinase Inhibitor (For Emphysema)	3/1/2022	5.45.09	<a href="#">FEP</a>
J0897	Prolia	denosumab	Oncology	3/1/2022	42885	<a href="#">CVS</a>
Q2043	Provenge	sipuleucel-t	Oncology	3/1/2022	39954	<a href="#">CVS</a>
J1301	Radicava	edaravone	Enzyme Replacement Therapy	3/1/2022	5.75.20	<a href="#">CVS</a>
Q5125	Releuko	filgrastim-ayow	Colony-Stimulating Factors	1/1/2024	5.85.010	<a href="#">CVS</a>
J1745	Remicade	infliximab	Autoimmune	3/1/2022	5.50.002	<a href="#">CVS</a>

HCPCS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J3285	Remodulin	treprostinil	Pulmonary Arterial Hypertension	3/1/2022	5.40.17	<a href="#">CVS</a>
Q5104	Renflexis	infliximab-abda	Autoimmune	3/1/2022	5.50.002	<a href="#">CVS</a>
Q5106	Retacrit	epoetin alfa-epbx	Erythropoiesis-Stimulating Agents	3/1/2022	5.85.06	<a href="#">CVS</a>
J3490	Revatio	sildenafil	Pulmonary Arterial Hypertension	3/1/2022	5.40.11	<a href="#">CVS</a>
Q5123	Riabni	rituximab-arrx	Oncology	1/1/2024	5.21.010	<a href="#">CVS</a>
J9312	Rituxan	rituximab	Oncology	3/1/2022	5.21.2010	<a href="#">CVS</a>
J9311	Rituxan Hycela	rituxumab hyaluronidase	Oncology	3/1/2022	5.21.096	<a href="#">CVS</a>
J1449	Rolvedon	eflapegrastim-xnst		1/1/2024	5.85.047	<a href="#">CVS</a>
J0596	Ruconest	c1 esterase inhibitor (recombinant)	Hereditary Angioedema	3/1/2022	5.85.17	<a href="#">CVS</a>
Q5119	Ruxience	rituximab-pvvr	Oncology	3/1/2022	5.21.2010	<a href="#">CVS</a>
J2353	Sandostatin LAR Depot	octreotide lar	Gastrointestinal: Chemoprotectant/ Hormonal	3/1/2022	39963	<a href="#">CVS</a>
J2502	Signifor LAR	pasireotide	Hormones	3/1/2022	46172	<a href="#">CVS</a>
J1602	Simponi Aria	golimumab	BDAID	3/1/2022	5.70.51	<a href="#">CVS</a>
J2327	Skyrizi IV	risankizumab-rzaa		10/1/2023	5.90.038	<a href="#">CVS</a>
J7331	Sodium Hyaluronate	sodium hyaluronate	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
J1300	Soliris	eculizumab	Hematology	3/1/2022	5.85.11	<a href="#">CVS</a>
J1930	Somatuline depot	lanreotide	Endocrine Disorders	3/1/2022	46537	<a href="#">CVS</a>
J2326	Spinraza	nusinersen	CNS Agents: Rare Diseases	3/1/2022	5.75.15	<a href="#">FEP</a>
J3358	Stelara IV	ustekinumab	BDAID: Crohns Disease/Ulcerative Colitis	3/1/2022	5.90.04	<a href="#">CVS</a>
J3490	Strensiq	asfotase alfa	Rare Disease	3/1/2022	42154	<a href="#">CVS</a>
J7321	Supartz FX	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
J1627	Sustol	granisetron extended-release	Antiemetics	3/1/2022	5.50.15	<a href="#">CVS</a>
90378	Synagis	palivizumab	Immunizing Agent	3/1/2022	38127	<a href="#">CVS</a>
J7331	Synojoint	sodium hyaluronate	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
J7325	Synvisc	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
J7325	Synvisc One	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
J9022	Tecentriq	atezolizumab	Oncology	3/1/2022	29362	<a href="#">CVS</a>
J3490	Tegsedi	inotersen	TRR Amyloidosis	1/1/2023	5.75.025	<a href="#">CVS</a>
J3241	Tepezza	teprotumumab-trbw	Rare Disease	3/1/2022	23527	<a href="#">CVS</a>
S0189	Testopel	testosterone pellets	Endocrine Disorders	3/1/2022	48729	<a href="#">CVS</a>
Q5116	Trazimera	trastuzumab-qyyp	Oncology	3/1/2022	5.21.2006	<a href="#">CVS</a>
J9033	Treanda	bendamustine	Oncology	3/1/2022	52372	<a href="#">CVS</a>
J7332	Triluron	sodium hyaluronate	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>

HCPDS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J9317	Trodelyv	sacituzumab govitecan-hziy	Oncology	3/1/2022	5.21.145	<a href="#">CVS</a>
Q5115	Truxima	rituxumab-abbs	Oncology	3/1/2022	5.21.2010	<a href="#">CVS</a>
J2323	Tysabri	natalizumab	Multiple Sclerosis	3/1/2022	5.60.13	<a href="#">CVS</a>
Q5111	Udenyca	pegfilgrastim-cbqv	Colony-Stimulating Factors	3/1/2022	5.85.009	<a href="#">CVS</a>
J1303	Ultomiris	ravulizumab-cwvz	Rare Disease	3/1/2022	5.85.33	<a href="#">CVS</a>
J1823	Uplizna	inebilizumab-cdon	Rare Disease	3/1/2022	5.99.18	<a href="#">FEP</a>
J2777	Vabysmo	faricimab-svoa	Ophthalmic Injections	1/1/2024	5.90.026	<a href="#">CVS</a>
J9303	Vectibix	panitumumab	Oncology	3/1/2022	31188	<a href="#">CVS</a>
Q5129	Vegzelma	bevacizumab-adcd	Oncology	1/1/2024	5.21.004	<a href="#">CVS</a>
J9041	Velcade	bortezomib	Oncology	3/1/2022	53103	<a href="#">CVS</a>
J1325	Veletri	epoprostenol	Pulmonary Arterial Hypertension	3/1/2022	5.40.15	<a href="#">CVS</a>
J7321	Visco-3	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	<a href="#">CVS</a>
J3385	Vpriv	velaglucerase alfa	Enzyme Replacement Therapy	3/1/2022	5.85.12	<a href="#">CVS</a>
J3032	Vyepti	eptinezumab-jjmr	CNS Agents: Migraine	3/1/2022	5.70.81	<a href="#">CVS</a>
J1429	Vyondys-53	golodirsen	CNS Agents: Rare Diseases	3/1/2022	5.75.31	<a href="#">CVS</a>
J9332	Vyvgart	efgartigimod alfa-fcab	Neurologic Disorders	1/1/2023	5.99.026	<a href="#">FEP</a>
J3590	Vyvgart Hytrulo	efgartigimod alfa and hyaluronidase-qvfc	Neurologic Disorders	1/1/2024	5.99.026	<a href="#">FEP</a>
J1558	Xembify	immune globulin human - klhw	Immune Globulin	3/1/2022	43972	<a href="#">CVS</a>
J0588	Xeomin	incobotulinumtoxina	Botulinum Toxins	3/1/2022	5.75.04	<a href="#">CVS</a>
J0897	Xgeva	denosumab	Oncology	3/1/2022	42885	<a href="#">CVS</a>
J2357	Xolair	omalizumab	Asthma/COPD	3/1/2022	5.45.02	<a href="#">CVS</a>
J9228	Yervoy	ipilimumab	Oncology	3/1/2022	41415	<a href="#">CVS</a>
J9352	Yondelis	trabectedin	Oncology	3/1/2022	23883	<a href="#">CVS</a>
J9400	Zaltrap	ziv-aflibercept	Oncology	3/1/2022	45798	<a href="#">CVS</a>
Q5101	Zarxio	filgrastim-sndz	Colony-Stimulating Factors	3/1/2022	5.85.010	<a href="#">CVS</a>
J0256	Zemaira	alpha 1-proteinase inhibitor	Alpha-1 Proteinase Inhibitor (For Emphysema)	3/1/2022	5.45.09	<a href="#">CVS</a>
J9223	Zepzelca	lurbinectedin	Oncology	3/1/2022	5.21.152	<a href="#">CVS</a>
Q5120	Ziextenzo	pegfilgrastim-bmez	Colony-Stimulating Factors	3/1/2022	5.85.009	<a href="#">CVS</a>
Q5118	Zirabev	bevacizumab-bvzr	Oncology	3/1/2022	38128	<a href="#">CVS</a>
J9202	Zoladex	goserelin acetate implant	Oncology	3/1/2022	50920	<a href="#">CVS</a>
J3399	Zolgensma	onasemnogene abeparvovec	Rare Disease	3/1/2022	5.75.27	<a href="#">FEP</a>

Other drugs may require prior approval through Arkansas Blue Cross and Blue Shield, and the above list subject to change.

To view additional resources, please visit [arkansasbluecross.com/providers/resource-center/specialty-pharmacy](https://arkansasbluecross.com/providers/resource-center/specialty-pharmacy).

00342.04.01-v092624-0736